A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia

William J. Panenka; Babak Khorram; Alasdair M. Barr; Geoffrey N. Smith; Donna J. Lang; Lili C. Kopala; Robert A. Vandorpe; William G. Honer

doi:10.1016/j.schres.2007.05.002

A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia

William J. Panenka, Babak Khorram, Alasdair M. Barr, Geoffrey N. Smith, Donna J. Lang, Lili C. Kopala, Robert A. Vandorpe, William G. Honer

Medicine

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Background: Previous studies have reported that hippocampal volumes correlate with symptom severity in schizophrenia. This longitudinal study measured changes in symptoms and hippocampal volume in patients switched from typical antipsychotics to olanzapine. Methods: MRI scans were acquired from patients with chronic schizophrenia (n = 10) and healthy volunteers (n = 20). At baseline, patients were treated with typical antipsychotics for at least one year, then switched to olanzapine, and rescanned approximately one year later. Results: Olanzapine treatment resulted in no significant change in right or left hippocampal volume. Individual changes in right hippocampal volume correlated significantly with changes in symptoms. Conclusions: Hippocampal volume change may serve as a marker of symptom change in patients on olanzapine.

Original language	English
Pages (from-to)	288-292
Number of pages	5
Journal	Schizophrenia Research
Volume	94
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2007.05.002
Publication status	Published - Aug 2007

Bibliographical note

Funding Information:
Dr. Honer reports receiving consulting fees or sitting on paid advisory boards for In-silico, Wyeth, Janssen and AstraZeneca, receiving lecture fees from Janssen and AstraZeneca, and educational grant support from Janssen, Eli Lilly and AstraZeneca.

Funding Information:
Dr. Honer was supported by NET-54013 from the Canadian Institutes of Health Research, and by the Michael Smith Foundation for Health Research, NARSAD, the Stanley Medical Research Institute, and the Norma Calder Foundation. A Clinical Scientist Award from Dalhousie University supported Dr. Kopala. Partial funding for MRI scanning was provided by investigator-initiated grants from Janssen-Ortho Canada and Eli Lilly Canada. The Queen Elizabeth-II Hospital Health Science Research Foundation and the Department of Psychiatry, Dalhousie University provided additional funding for scanning. None of the above funding sources had any further role in the study; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

ASJC Scopus Subject Areas

Psychiatry and Mental health
Biological Psychiatry

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.schres.2007.05.002

Cite this

@article{6ce071ded36b4b45816f42741d9de4e4,

title = "A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia",

abstract = "Background: Previous studies have reported that hippocampal volumes correlate with symptom severity in schizophrenia. This longitudinal study measured changes in symptoms and hippocampal volume in patients switched from typical antipsychotics to olanzapine. Methods: MRI scans were acquired from patients with chronic schizophrenia (n = 10) and healthy volunteers (n = 20). At baseline, patients were treated with typical antipsychotics for at least one year, then switched to olanzapine, and rescanned approximately one year later. Results: Olanzapine treatment resulted in no significant change in right or left hippocampal volume. Individual changes in right hippocampal volume correlated significantly with changes in symptoms. Conclusions: Hippocampal volume change may serve as a marker of symptom change in patients on olanzapine.",

author = "Panenka, {William J.} and Babak Khorram and Barr, {Alasdair M.} and Smith, {Geoffrey N.} and Lang, {Donna J.} and Kopala, {Lili C.} and Vandorpe, {Robert A.} and Honer, {William G.}",

note = "Funding Information: Dr. Honer reports receiving consulting fees or sitting on paid advisory boards for In-silico, Wyeth, Janssen and AstraZeneca, receiving lecture fees from Janssen and AstraZeneca, and educational grant support from Janssen, Eli Lilly and AstraZeneca. Funding Information: Dr. Honer was supported by NET-54013 from the Canadian Institutes of Health Research, and by the Michael Smith Foundation for Health Research, NARSAD, the Stanley Medical Research Institute, and the Norma Calder Foundation. A Clinical Scientist Award from Dalhousie University supported Dr. Kopala. Partial funding for MRI scanning was provided by investigator-initiated grants from Janssen-Ortho Canada and Eli Lilly Canada. The Queen Elizabeth-II Hospital Health Science Research Foundation and the Department of Psychiatry, Dalhousie University provided additional funding for scanning. None of the above funding sources had any further role in the study; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. ",

year = "2007",

month = aug,

doi = "10.1016/j.schres.2007.05.002",

language = "English",

volume = "94",

pages = "288--292",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia

AU - Panenka, William J.

AU - Khorram, Babak

AU - Barr, Alasdair M.

AU - Smith, Geoffrey N.

AU - Lang, Donna J.

AU - Kopala, Lili C.

AU - Vandorpe, Robert A.

AU - Honer, William G.

N1 - Funding Information: Dr. Honer reports receiving consulting fees or sitting on paid advisory boards for In-silico, Wyeth, Janssen and AstraZeneca, receiving lecture fees from Janssen and AstraZeneca, and educational grant support from Janssen, Eli Lilly and AstraZeneca. Funding Information: Dr. Honer was supported by NET-54013 from the Canadian Institutes of Health Research, and by the Michael Smith Foundation for Health Research, NARSAD, the Stanley Medical Research Institute, and the Norma Calder Foundation. A Clinical Scientist Award from Dalhousie University supported Dr. Kopala. Partial funding for MRI scanning was provided by investigator-initiated grants from Janssen-Ortho Canada and Eli Lilly Canada. The Queen Elizabeth-II Hospital Health Science Research Foundation and the Department of Psychiatry, Dalhousie University provided additional funding for scanning. None of the above funding sources had any further role in the study; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

PY - 2007/8

Y1 - 2007/8

N2 - Background: Previous studies have reported that hippocampal volumes correlate with symptom severity in schizophrenia. This longitudinal study measured changes in symptoms and hippocampal volume in patients switched from typical antipsychotics to olanzapine. Methods: MRI scans were acquired from patients with chronic schizophrenia (n = 10) and healthy volunteers (n = 20). At baseline, patients were treated with typical antipsychotics for at least one year, then switched to olanzapine, and rescanned approximately one year later. Results: Olanzapine treatment resulted in no significant change in right or left hippocampal volume. Individual changes in right hippocampal volume correlated significantly with changes in symptoms. Conclusions: Hippocampal volume change may serve as a marker of symptom change in patients on olanzapine.

AB - Background: Previous studies have reported that hippocampal volumes correlate with symptom severity in schizophrenia. This longitudinal study measured changes in symptoms and hippocampal volume in patients switched from typical antipsychotics to olanzapine. Methods: MRI scans were acquired from patients with chronic schizophrenia (n = 10) and healthy volunteers (n = 20). At baseline, patients were treated with typical antipsychotics for at least one year, then switched to olanzapine, and rescanned approximately one year later. Results: Olanzapine treatment resulted in no significant change in right or left hippocampal volume. Individual changes in right hippocampal volume correlated significantly with changes in symptoms. Conclusions: Hippocampal volume change may serve as a marker of symptom change in patients on olanzapine.

UR - http://www.scopus.com/inward/record.url?scp=34447098550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447098550&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2007.05.002

DO - 10.1016/j.schres.2007.05.002

M3 - Article

C2 - 17570643

AN - SCOPUS:34447098550

SN - 0920-9964

VL - 94

SP - 288

EP - 292

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1-3

ER -

A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this